

Late-Breaker Abstract Presentations

Late-breaker abstracts have been added to previously programmed poster and slide sessions as appropriate.

Poster Session

4(A). Antifungal Pharmacokinetics/Dynamics

Saturday, 12:15 p.m. – 1:15 p.m. Hall C

- A-021a** Efficacy of the Combination of Voriconazole and Anidulafungin in Experimental Invasive Pulmonary Aspergillosis in Neutropenic Rats
W. VAN DE SANDE, R. MATHOT, M. TEN KATE, W. VAN VIANEN, M. TAVAKOL, B. RIJNDERS, I. BAKKER-WOUDENBERG; Erasmus MC, Rotterdam, Netherlands.

Poster Session

6(B). Therapy of Bacterial Infections in Animal Models

Saturday, 12:15 p.m. – 1:15 p.m. Hall C

- B-069a** Disruption of Quorum Sensing by a Fully Human Monoclonal Antibody can Attenuate Virulence in an In Vivo Model of *Pseudomonas aeruginosa* Lung Infection
I. D. BROADBENT¹, G. STRACHAN², J. STEVEN¹, R. ALLAN¹, S. PALLIYIL³, J. PARK¹, R. A. PARR¹, S. CHOI⁴, S. JEON⁴, O. CHOI⁴, A. J. R. PORTER²; ¹Wyeth Res., Aberdeen, United Kingdom, ²Haptogen Ltd., Aberdeen, United Kingdom, ³Univ. of Aberdeen, Aberdeen, United Kingdom, ⁴Daewoong Pharmaceutical Co., Kyunggi-Do, Republic of Korea.

Poster Session

7(B). Virulence Mechanisms of Bacterial Pathogens

Saturday, 12:15 p.m. – 1:15 p.m. Hall C

- B-087a** Cyclic AMP Intoxication of Macrophages by a *Mycobacterium tuberculosis* Adenylate Cyclase
N. AGARWAL, W. BISHAI; Johns Hopkins Univ., Baltimore, MD.

Poster Session

18(C2). Vancomycin MIC-CREEP and Resistance in *Staphylococcus aureus*

Saturday, 12:15 p.m. – 1:15 p.m. Hall C

- C2-278** Lack of Heteroresistance among *Staphylococcus aureus* Isolates with Vancomycin MICs of 2 µg/mL by Automated Testing
S. SATOLA^{1,2}, E. BURD¹, M. FARLEY^{1,2}, A. CALIENDO¹; ¹Emory Univ., Atlanta, GA, ²Atlanta VAMC, Decatur, GA.

Poster Session

19(D). β-Lactamase Detection in the Clinical Laboratory

Saturday, 12:15 – 1:15 p.m. Hall C

- D-291a** Clinical Validation of a LightCycler Assay for the Rapid Detection of KPC Producing *Enterobacteriaceae* from Cultured Isolates
S. A. CUNNINGHAM¹, P. C. KOHNER¹, L. M. NYRE¹, E. A. VETTER¹, E. J. L. ROBBERTS¹, G. F. WELDHAGEN², R. PATEL¹; ¹Mayo Fndn., Rochester, MN, ²AMPATH Natl. Lab. Services, Pretoria, South Africa.
- D-291b** Use of NXL104, a β-Lactamase Inhibitor, to Detect *Klebsiella pneumoniae* Carbapenemase (KPC) in *Enterobacteriaceae*
P. LEVASSEUR¹, C. MIOSSEC¹, A. GIRARD¹, D. SHLAES²; ¹Novoxel SA, Romainville, France, ²Anti-Infectives Consulting, Stonington, CT.

Poster Session

27(G). Vaccines for Adults

Saturday, 12:15 p.m. – 1:15 p.m. Hall C

- G-399b** Immunogenicity of a Psoralen-Inactivated Dengue-1 Virus Vaccine Candidate in *Aotus nancymae* Monkeys
R. C. MAVES, R. M. CASTILLO ORÉ, T. J. KOCHER; U.S. Naval Med. Res. Ctr. Detachment, Lima, Peru.
- G-399c** Safety and Immunogenicity of MenACWY-CRM Administered Sequentially or Concomitantly with Tdap and HPV Vaccines
A. ARGUEDAS¹, C. SOLEY¹, C. LOAIZA¹, G. RINCON¹, S. GUEVARA¹, A. PEREZ¹, W. PORRAS¹, O. ALVARADO¹, L. AGUILAR¹, A. ABDELNOUR¹, U. GRUNWALD², L. BEDELL², P. DULL²; ¹Inst. de Atención Pediátrica, San José, Costa Rica, ²Novartis Vaccines and Diagnostics, Inc., Cambridge, MA.
- G-399d** Concomitant Administration of Zoster and Pneumococcal Vaccines in Adults ≥ 60 Years Old
R. MANINTYRE¹, T. EGERTON², M. MCCAUGHEY³, J. PARRINO⁴, B. CAMPBELL⁴, S. SU⁴, M. PAGNONI⁴, J. STEK⁴, J. XU⁴, I. CHAN⁴, J. SILBER⁴; ¹Univ. of New S. Wales, Sydney, Australia, ²Priory Res., Belfast, Ireland, ³Randalstown Hlth. Ctr., Antrim, United Kingdom, ⁴Merck, N. Wales, PA.

Poster Session

28(G1). Pediatric Vaccines

Saturday, 12:15 p.m. – 1:15 p.m. Hall C

- G1-442a** Safety, Reactogenicity and Immunogenicity of RIX4414 Live Attenuated Human Rotavirus Vaccine in Pre-Term Infants
E. OMENACA¹, J. WYSOCKI², J. SARLANGUE³, M. NOGUEIRA⁴, P. SURYAKIRAN⁵, I. SMOLENOV⁵, H. HAN⁵; ¹La Paz Hosp., Madrid, Spain, ²Univ. Sch. of Med. Sci. & Regional Med. Ctr. for Mother and Child, Poznan, Poland, ³Hôsp. des Enfants, CHU Bordeaux, Bordeaux, France, ⁴Maternidade Alfredo da Costa, Lisbon, Portugal, ⁵GlaxoSmithKline Biologicals, Rixensart, Belgium.
- G1-442b** Safety, Reactogenicity and Immunogenicity of Live Attenuated Human Rotavirus Vaccine RIX4414 in HIV+ Infants in South Africa
A. STEELE¹, P. BOS², J. TUMBO², S. MADHI³, C. LOUW⁴, C. WERNER², P. SURYAKIRAN⁵, A. DELEM⁵, H. HAN⁵; ¹WHO, Geneva, Switzerland, ²Univ. of Limpopo, Pta, South Africa, ³Univ. of Witwatersrand, Jhb, South Africa, ⁴MCR, Brits, South Africa, ⁵GlaxoSmithKline Bio, Rixensart, Belgium.

Poster Session

33(K). Epidemiology and Management of *C. difficile*

Saturday, 12:15 p.m. – 1:15 p.m. Hall C

K-524a Clinical and Microbiological Epidemiology of *Clostridium difficile*-Associated Diarrhea in Brighton, UK
G. SATTA, V. WILSON, M. CUBBON, M. J. LEWELYN; Brighton and Sussex Univ. Hosp. NHS Trust, Brighton, United Kingdom.

K-524b Nitazoxanide (N) vs. Vancomycin (V) to Treat (Rx) *Clostridium difficile* Disease (CDD)

D. MUSER¹, N. LOGAN¹, A. BRESSLER², D. JOHNSON³, J. F. ROSSIGNOL⁴; ¹VA Med. Ctr., Houston, TX, ²VA Med. Ctr., Bay Pines, TX, ³DeKalb Med. Ctr., Decatur, GA, ⁴Romark Inst., Tampa, FL.

Poster Session

39(K). Surgical Site Infections: Trials and Tribulations

Saturday, 12:15 p.m. – 1:15 p.m. Hall C

K-601a A Comparison of Two Antiseptic Preparations for Prevention of Surgical Site Infections

R. DAROUICHE¹, M. WALL², K. ITANI³, M. OTTERSON⁴, A. WEBB⁵, C. CROSBY⁶, M. MOSIER⁷, A. ALSHARIF¹, D. BERGER⁸; ¹Baylor Coll. of Med., Houston, TX, ²Ben Taub Gen. Hosp., Houston, TX, ³VA Boston Healthcare System, West Roxbury, MA, ⁴Med. Coll. of Wisconsin, Milwaukee, WI, ⁵VA Med. Ctr., Atlanta, GA, ⁶Cardinal Hlth., Leawood, KS, ⁷Washburn Univ., Topeka, KS, ⁸Michael E. DeBakey VA Med. Ctr., Houston, TX.

Poster Session

41(L). Aggressive Unusual Infections from Around the World

Saturday, 12:15 p.m. – 1:15 p.m. Hall C

L-626a Burulico Drug Trial for *M ulcerans* Infection, Ghana: Interim Results

W. A. NIENHUIS¹, Y. STIENSTRA¹, W. A. THOMPSON², P. C. AWUAH³, E. O. AMPADU⁴, N. Y. AWUA-BOATENG^{5,6}, G. BRETZEL⁶, O. ADJEI⁷, T. S. VAN DER WERF¹; ¹UMCG, Univ. of Groningen, Groningen, Netherlands, ²Agogo Presbyterian Hosp., Agogo, Ghana, ³Nkawie Government Hosp., Nkawie, Ghana, ⁴NBUCP, Accra, Ghana, ⁵KCCR, KNUST, Kumasi, Ghana, ⁶DITM, Munich, Germany, ⁷KCCR, KNUST, Kumasi, Ghana.

Poster Session

42(L). New Issues with Central Nervous System Infections

Saturday, 12:15 p.m. – 1:15 p.m. Hall C

L-644a Characterization of the *Neisseria meningitidis* Serogroup B Epidemic in Oregon

M. A. SCHMIDT¹, J. TIERHEIMER², A. R. THOMAS¹, P. R. CIESLAK¹; ¹Oregon Dept. of Human Services, Portland, OR, ²Oregon State Publ. Hlth. Lab., Hillsboro, OR.

Poster Session

43(L). Sexually Transmitted Infections: Obstetric and Gynecological Infections

Saturday, 12:15 p.m. – 1:15 p.m. Hall C

L-651a Group B Streptococcus Detection: Implementation of RT-PCR in Delivery Room Compare to Prenatal Screening
S. GERBER, M. BLUMBERG, G. PROD'HOM, A. WENGER, J. WASSERFALLEN; CHUV, Lausanne, Switzerland.

Poster Session

44(L). The World of Community-Acquired Pneumonia

Saturday, 12:15 p.m. – 1:15 p.m. Hall C

L-662a Superiority of an Antibiotic (faropenem medoxomil) versus Placebo in the Treatment of AECB

R. M. ECHOLS¹, R. TOSIELLO¹, M. GARFIELD¹, K. WAY¹, A. RUTKOWSKI², S. KOWALSKY¹; ¹Replidyne, Inc., Louisville, CO, ²INC Res., Raleigh, NC.

Poster Session

45(M). Diagnostic Mycology

Saturday, 12:15 p.m. – 1:15 p.m. Hall C

M-710a Utility of a Pan-Fungal PCR for Identification of Fungi from Fresh and Fixed Tissue

F. KAKKAR, F. GHARABAGHI, S. E. RICHARDSON; Hosp. for Sick Children, Toronto, Canada.

Slide Session

78(B). Mycobacteria: New Therapies, Mechanisms and Models

Sunday, 8:30 a.m. – 11:00 a.m. Independence I (Grand Hyatt)

11:00 a.m.

B-881a Extended Early Bactericidal Activity (EBA) of PA-824, a Novel Drug for Tuberculosis Treatment

A. GINSBERG¹, A. DIACON², R. DAWSON³, K. WHITNEY⁴, D. ROUSE⁴, M. LAURENZI¹, C. VAN NIEKERK⁵, J. S. MARITZ⁶, A. VENTER², P. DONALD², M. SPIGELMAN¹; ¹Global Alliance for TB Drug Dev., New York, NY, ²Univ. of Stellenbosch, Cape Town, South Africa, ³Univ. of Cape Town, Cape Town, South Africa, ⁴RTI Intl., Research Triangle Park, NC, ⁵Global Alliance for TB Drug Dev., Pretoria, South Africa, ⁶Med. Res. Council, Cape Town, South Africa.

11:15 a.m.

B-881b Interim Analysis of a Double-Blind, Placebo-Controlled Study with TMC207 in Patients with Multi-Drug Resistant (MDR) Tuberculosis

A. H. DIACON¹, A. PYM², M. GROBUSCH³, M. BOGOSHI⁴, R. KRAUSE⁵, C. PISTORIUS³, T. DE MAREZ⁶, N. LOUNIS⁷, R. VAN HEESWIJK⁷, P. MEYVISCH⁷, K. DE BEULE⁷, K. ANDRIES⁷, D. F. MCNEELEY⁸; ¹Stellenbosch Univ. Faculty of Hlth. Sci., Tygerberg, South Africa, ²Med. Res. Council, Durban, South Africa, ³Univ. of Witsersrand and NHLS, Johannesburg, South Africa, ⁴Aurum Hlth., Johannesburg, South Africa, ⁵QdotPharma, George, South Africa, ⁶Tibotec, Yardley, PA, ⁷Tibotec, Mechelen, Belgium.

Slide Session

80(H). Antiretroviral Therapy

Sunday, 8:30 a.m. – 11:00 a.m. Independence A (Grand Hyatt)

10:30 a.m.

H-896a STARTMRK, A Phase III Study of the Safety & Efficacy of Raltegravir (RAL)-Based vs Efavirenz (EFV)-Based Combination Therapy in Treatment-Naïve HIV-Infected Patients

J. LENNOX¹, E. DEJESUS², A. LAZZARIN³, R. POLLARD⁴, J. MADRUGA⁵, J. ZHAO⁶, X. XU⁶, A. WILLIAMS-DIAZ⁶, A. RODGERS⁶, M. DINUBILE⁶, B. NGUYEN⁶, R. LEAVITT⁶, P. SKLAR⁶; ¹Emory Univ., Atlanta, GA, ²Orlando Immunology Ctr., Orlando, FL, ³Univ. Vita-Salute San Raffaele, Milan, Italy, ⁴UC Davis, Sacramento, CA, ⁵Ctr. de Referencia d Treinamento DST/AIDS, Sao Paulo, Brazil, ⁶Merck Res. Labs, North Wales, PA.

10:45 a.m.

H-896b Initiating Rather than Deferring Haart at a CD4+ Count Between 351-500 Cells/mm³ is Associated with Improved Survival

M. M. KITAHATA¹, S. J. GANGE², R. D. MOORE², The North American Aids Cohort Collaboration on Research and Design; ¹Univ. of Washington, Seattle, WA, ²Johns Hopkins Univ., Baltimore, MD.

Poster Session

91(A). HIV Pharmacokinetics/Dynamics

Sunday, 11:15 a.m. – 12:15 p.m. Hall C

A-967a Pharmacokinetic Interactions between Buprenorphine/Naloxone & Tipranavir/Ritonavir in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone

R. BRUCE¹, F. ALTICE¹, D. MOODY², S. LIN², W. FANG², J. S. SABO³, J. WRUCK³, C. CONNER³, P. PILIERO³, L. ANDREWS¹, G. FRIEDLAND¹; ¹Yale Univ., New Haven, CT, ²Univ. of Utah, Salt Lake City, UT, ³Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.

Poster Session

93(B). Antistaphylococcal Therapy Testing in Animal Models

Sunday, 11:15 a.m. – 12:15 p.m. Hall C

B-1013a Nona-D-Arginine Therapy for *Pseudomonas aeruginosa* Corneal Disease

J. A. HOBDEN, P. KARICHERLA; LSU Hlth.Sci. Ctr., New Orleans, LA.

Poster Session

96(C1). *Pseudomonas aeruginosa*

Sunday, 11:15 a.m. – 12:15 p.m. Hall C

C1-1065a Sequential Exposure to Colistin (C) and Meropenem (M) Restores Carbapenem Susceptibility of Carbapenem-Resistant *Pseudomonas aeruginosa* (CRP)

M. A. ULLMAN, L. B. HOVDE, J. C. ROTSCHAFFER; Univ. of Minnesota, Minneapolis, MN.

Poster Session

98(C2). Linezolid and Other Resistance in *Staphylococcus aureus*

Sunday, 11:15 a.m. – 12:15 p.m. Hall C

C2-1087a Linezolid Non-Susceptible *Staphylococcus aureus* in Three Patients with Cystic Fibrosis Receiving Prolonged Linezolid Therapy

P. REVELL^{1,2}, T. W. COOPER¹; ¹Children's Med. Ctr. Dallas, Dallas, TX, ²The Univ. of Texas Southwestern Med. Sch., Dallas, TX.

Poster Session

101(D). Laboratory Testing for Mycobacteria

Sunday, 11:15 a.m. – 12:15 p.m. Hall C

D-1131a Urea Breath Testing as a Rapid Diagnostic in the Testing of *Mycobacterium tuberculosis*

M. JASSAL¹, G. NEDELTCHEV¹, Z. SHARP², W. BISHAI¹, G. S. TIMMINS²; ¹Johns Hopkins Sch. of Med., Baltimore, MD, ²Univ. of New Mexico, Albuquerque, NM.

D-1131b A Pyrosequencing Approach to Rapidly Assess Mutations in the *rpoB* Gene Associated with Rifampin Resistance in Clinical Specimens of *Mycobacterium tuberculosis*

T. A. HALSE, J. EDWARDS, J. R. DRISCOLL, V. ESCUYER, K. A. MUSSER; Wadsworth Ctr., Albany, NY.

Poster Session

103(F1). Investigational Anti-Virals and Anti-Mycobacterial Agents

Sunday, 11:15 a.m. – 12:15 p.m. Hall C

F1-1163a The Oxazolidinone PNU-100480 has Strong Bactericidal and Sterilizing Activity in the Murine Model of Tuberculosis (TB)

K. WILLIAMS¹, C. STOVER², S. BRICKNER³, T. ZHU³, R. TASNEEN¹, S. TYAGI¹, J. GROSSET¹, E. NUERMBERGER¹; ¹Johns Hopkins Sch. of Med., Baltimore, MD, ²Pfizer Inc., Kalamazoo, MI, ³Pfizer Inc., Groton, CT.

Poster Session

108(H). Antiretroviral Resistance and HIV Diagnostics

Sunday, 11:15 a.m. – 12:15 p.m. Hall C

H-1232a Reanalysis of the MERIT Study with the Enhanced Trofile Assay

M. SAAG¹, J. HEERA², J. GOODRICH², E. DEJESUS³, N. CLUMECK⁴, D. COOPER⁵, S. WALMSLEY⁶, N. TING², E. COAKLEY⁷, J. REEVES⁷, M. WESTBY⁸, E. VAN DER RYST⁸, H. MAYER²; ¹Univ. of Alabama, Birmingham, AL, ²Pfizer Global R&D, New London, CT, ³Orlando Immunology Ctr., Orlando, FL, ⁴Saint-Pierre Univ. Hosp., Brussels, Belgium, ⁵Univ. of New South Wales, Sydney, Australia, ⁶Univ. of Toronto, Toronto, Canada, ⁷Monogram BioSci., South San Francisco, CA, ⁸Pfizer Global R&D, Sandwich, United Kingdom.

Poster Session

109(H). Antiretroviral Therapy: Clinical Trials

Sunday, 11:15 a.m. – 12:15 p.m.

Hall C

H-1250a Atazanavir/Ritonavir (ATV/r) + Abacavir/Lamivudine (ABC/3TC) in Antiretroviral (ART)-Naïve HIV-1 Infected HLA-B*5701 Negative Subjects Demonstrates Efficacy and Safety: The ARIES Trial

K. SQUIRES¹, B. YOUNG², E. DEJESUS³, N. BELLOS⁴, D. MURPHY⁵, D. SUTHERLAND-PHILLIPS⁶, H. ZHAO⁶, L. PATEL⁶, L. ROSS⁶, P. WANNAMAKER⁶, M. SHAEFER⁶; ¹Thomas Jefferson Univ., Philadelphia, PA, ²Univ. of Colorado, Denver, CO, ³Orlando Immunology Ctr., Orlando, FL, ⁴Southwest Infectious Disease Association, Dallas, TX, ⁵Clinique Med. L'Actuel, Montreal, Canada, ⁶GlaxoSmithKline, Research Triangle Park, NC.

H-1250c ARTEMIS: Efficacy and Safety of Darunavir/ritonavir (DRV/r) 800/100 mg Once-Daily vs Lopinavir/Ritonavir (LPV/r) in Treatment-Naïve, HIV-1-Infected Patients at 96 Wks

A. MILLS¹, M. NELSON², D. JAYAWEEERA³, K. RUXRUNGTHAM⁴, I. CASSETTI⁵, P. GIRARD⁶, C. WORKMAN⁷, I. DIERYNCK⁸, V. SEKAR⁹, C. VANDEN ABEELE⁸, L. LAVREYS⁸; ¹Tibotec, CA, ²Tibotec, United Kingdom, ³Tibotec, FL, ⁴Tibotec, Thailand, ⁵Tibotec, Argentina, ⁶Tibotec, France, ⁷Tibotec, Australia, ⁸Tibotec, Belgium, ⁹Tibotec, PA.

H-1250d CASTLE: Atazanavir-Ritonavir vs Lopinavir-Ritonavir in Antiretroviral-Naïve HIV-1 Infected Patients: 96 Week Efficacy and Safety

J. MOLINA¹, J. ANDRADE-VILLANUEVA², J. ECHEVARRIA³, P. CHETCHOTISAKD⁴, J. CORRAL⁵, N. DAVID⁶, M. MANCINI⁷, R. YANG⁷, S. MCGRATH⁷, J. ABSALON⁷; Castle Study Team; ¹Saint-Louis Hosp., Paris, France, ²Hosp Civil De Guadalajara, Guadalajara, Mexico, ³Hosp. Natl. Cayetano Heredia, Lima, Peru, ⁴Khonkaen Univ., Khonkaen, Thailand, ⁵Hosp. Interzonal Gral De Agudos Oscar Alende, Buenos Aires, Argentina, ⁶Brooklyn Med. Ctr., Western Cape, South Africa, ⁷Bristol-Myers Squibb, Wallingford, CT.

H-1250e Switching from a 200mg-Ritonavir (RTV, r)-Boosted Fosamprenavir (FPV) Regimen (700mg/200mg BID or 1400mg/200mg QD) to a 100mg RTV-Boosted FPV Regimen (1400mg/100mg QD) Yields Similar Efficacy and Safety

C. COHEN¹, E. DEJESUS², A. LAMARCA³, L. SLOAN⁴, B. YOUNG⁵, D. SUTHERLAND-PHILLIPS⁶, L. DIX⁶, L. PATEL⁶, C. VAVRO⁶, P. WANNAMAKER⁶, M. SHAEFER⁶; ¹Community Res. Initiative, Boston, MA, ²Orlando Immunology Ctr., Orlando, FL, ³Therafirst Med. Ctr., Fort Lauderdale, FL, ⁴North Texas IDC, Dallas, TX, ⁵Univ. of Colorado, Denver, CO, ⁶GlaxoSmithKline, Research Triangle Park, NC.

Poster Session

111(H). Antiretroviral Therapy: New Agents

Sunday, 11:15 a.m. – 12:15 p.m.

Hall C

H-1269a Antiviral Activity and Tolerability of 5 mg/kg and 10 mg/kg Doses of PRO 140, a Humanized Monoclonal Antibody to CCR5

J. M. JACOBSON¹, M. A. THOMPSON², M. A. FISCHL³, M. S. SAAG⁴, B. S. ZINGMAN⁵, R. LIPORACE⁶, J. P. LALEZARI⁷, C. J. FICHTENBAUM⁸, D. S. BERGER⁹, N. STAMBLER¹⁰, Y. ROTSHTEYN¹⁰, P. D'AMBROSIO¹⁰, M. MICHAEL¹⁰, S. A. MORRIS¹⁰, P. J. MADDON¹⁰, W. C. OLSON¹⁰; ¹Drexel Univ. Coll. of Med., Philadelphia, PA, ²ARCA, Atlanta, GA, ³Univ. of Miami, Miami, FL, ⁴Univ. of Alabama, Birmingham, AL, ⁵Montefiore Med. Ctr., Bronx, NY, ⁶Albany Med. Ctr., Albany, NY, ⁷Quest Clinical Res., San Francisco, CA, ⁸Univ. of Cincinnati, Cincinnati, OH, ⁹NorthStar Med. Ctr., Chicago, IL, ¹⁰Progenics Pharmaceuticals, Tarrytown, NY.

Poster Session

114(G2). Pediatrics III

Sunday, 12:15 p.m. – 1:15 p.m.

Hall C

G2-1346a Lack of Efficacy of Primary Isoniazid (INH) Prophylaxis in Increasing Tuberculosis (TB) Free Survival in HIV-Infected (HIV+) South African Children

S. A. MADHI¹, S. NACHMAN², A. VIOLARI¹, C. MITCHELL³, M. F. COTTON⁴, R. BOBAT⁵, P. JEAN-PHILIPPE⁶, S. KIM⁷, G. MCSHERRY⁸, P1041 Team; ¹Univ. of Witwatersrand, Johannesburg, South Africa, ²SUNY, Stony Brook, NY, ³Univ. of Miami Sch. of Med., Miami, FL, ⁴Stellenbosch Univ., CT, South Africa, ⁵Univ. of Kwazulu Natal, KZN, South Africa, ⁶HJF-DAIDS, Bethesda, MD, ⁷Harvard Sch. Publ. Hlth., Boston, MA, ⁸NJ Med. Sch., Newark, NJ.

Poster Session

122(K). Solid Organ Transplant Infections

Sunday, 12:15 p.m. – 1:15 p.m.

Hall C

K-1475a Transplant-Associated LCMV Transmission: Massachusetts, 2008

S. SCHILLIE¹, E. FARNON¹, M. KUEHNERT¹, M. WONG², M. ARYA², A. GAUTAM³, C. SULIS³, P. TORMEY⁴, A. BARRY⁴; LCMV Transplant Investigation Team; ¹CDC, Atlanta, GA, ²Beth Israel Deaconess Med. Ctr., Boston, MA, ³Boston Med. Ctr., Boston, MA, ⁴Boston Publ. Hlth. Commission, Boston, MA.

K-1475b Significance of Positive Cultures from Organ Preservation Fluid in Solid Organ Transplantation

C. P. YANSOUNI, G. LIU, N. DENDUKURI, M. FERNANDEZ, C. FRENETTE, S. PARASKEVAS, D. C. SHEPPARD; McGill Univ., Montreal, Canada.

Poster Session

126(L). New Treatment Options in Skin and Soft Tissue Infections

Sunday, 12:15 p.m. – 1:15 p.m. Hall C

- L-1515a** CANVAS-1: Randomized, Double-Blinded, Phase 3 Study (P903-06) of the Efficacy and Safety of Ceftaroline vs. Vancomycin plus Aztreonam in Complicated Skin and Skin Structure Infections (cSSSI)
G. R. COREY¹, M. WILCOX², G. H. TALBOT³, T. BACULIK³, D. THYE³; ¹Duke Clinical Res. Inst., Durham, NC, ²Univ. of Leeds, Leeds, United Kingdom, ³Cerexa, Inc., Alameda, CA.
- L-1515b** Safety and Efficacy of PTK 0796: Results of the Phase 2 Study in Complicated Skin and Skin Structure Infections Following IV and Oral Step-Down Therapy – Boston, MA
R. D. ARBEIT, J. A. ROBERTS, A. R. FORSYTHE, S. M. JOHNSTON, F. SEYEDI, M. PUKSHANSKY, S. K. TANAKA; Paratek Pharmaceuticals, Inc, Boston, MA.
- L-1515c** A Phase 2 Study Comparing Two Doses of Radezolid to Linezolid in Adults with Uncomplicated Skin and Skin Structure Infections (uSSSI)
T. FILE JR.¹, F. BAGHERI², L. BUSH³, J. DESANTO⁴, A. MARKOWITZ⁵, B. MERRICK⁶, J. PULLMAN⁷, R. TOPKIS⁸, E. BURAK⁹, S. HOPKINS⁹; ¹Summa Hlth. System, Akron, OH, ²Jamaica Hosp Med Ctr., Jamaica, NY, ³S Flor Clin. Res, Atlantis, FL, ⁴Healthcare Partners Med. Group, Pasadena, CA, ⁵Private Practice, Keego Harbor, MI, ⁶McKenzie Med Ctr., Sylmar, CA, ⁷Mercury St. Med. Group, Butte, MT, ⁸Warminster Med. Assoc., Warminster, PA, ⁹Rib-X, New Haven, CT.

Slide Session

138(B). Basic Mechanisms of Bacterial Toxin Action

Sunday, 1:30 p.m. – 4:00 p.m. Independence E (Grand Hyatt)

3:45 p.m.

- B-1682a** Therapeutic Efficacy of MDX-1303, an Anti-Toxin Monoclonal Antibody, for Inhalational Anthrax in the New Zealand White (NZW) Rabbit Model
D. BLANSET¹, C. R. BIGGER², G. STARK², M. G. MELDORF³, V. D. RIDDLE³, I. LOWY¹; ¹Medarex, Inc., Bloomsbury, NJ, ²Battelle Bio Med. Res. Ctr., Columbus, OH, ³PharmAthene, Inc., Annapolis, MD.

Slide Session

177(C2). MRSA and Other Resistant Bacteria in Animals and Man

Monday, 8:30 a.m. – 11:00 a.m. Room 151B

10:30 a.m.

- C2-1835a** Outbreak of Linezolid-Resistant *Staphylococcus aureus* in Intensive Care
M. DE LA TORRE, M. SANCHEZ, G. MORALES, E. BAOS, A. ARRIBI, N. GARCÍA, R. ANDRADE, B. PELAEZ, M. P. PACHECO, S. DOMINGO, J. CONESA, M. NIETO, F. J. CANDEL, J. PICAZO; Hosp. Clínico San Carlos, Madrid, Spain.

Slide Session

180(V). New and Old Viruses

Monday, 8:30 a.m. – 11:00 a.m. Independence I (Grand Hyatt)

10:30 a.m.

- V-1862a** Preclinical and Clinical Development of a Humanized Monoclonal Antibody for Treatment of West Nile Virus Infection
J. L. NORDSTROM¹, L. BRASHEARS¹, K. GAY¹, S. R. PILLEMER¹, D. A. CARLIN¹, H. LI¹, S. JOHNSON¹, B. G. MATTHEWS², M. S. DIAMOND³, J. D. MORREY⁴; ¹MacroGenics, Rockville, MD, ²BioDirect, Silver Spring, MD, ³Washington Univ. Sch. Med., St. Louis, MO, ⁴Utah State Univ., Logan, UT.

10:45 a.m.

- V-1862b** Evidence of Positive Selection in Influenza A/H3N2 Evolution in US Dept. of Defense (DoD) Populations 2006-2008
J. L. GARNER¹, Y. I. WOLF², A. OWENS¹, V. L. HEADLEY¹, D. LIPMAN²; ¹US Air Force Sch. of Aerospace Med., Brooks City-Base, TX, ²Natl. Ctr. for Biotechnology Information/NIH, Bethesda, MD.

Poster Session

188(C1). Mechanisms of Antibacterial Resistance

Monday, 11:15 a.m. – 12:15 p.m. Hall C

- C1-1951a** Integron-Mobilization Unit as a Source of Mobility of Antibiotic Resistance Gene

L. POIREL¹, A. CARRER¹, J. D. PITOUT², P. NORDMANN¹; ¹Lab. de Bacteriologie, INSERM U914, Le Kremlin Bicetre, France, ²Univ. of Calgary, Calgary, Canada.

Poster Session

196(F1). Oxazolidinones

Monday, 11:15 a.m. – 12:15 p.m. Hall C

- F1-2069a** Hematological Effects of TR-701, Linezolid and Placebo Administered for 21 Days in Healthy Subjects

P. PROKOCIMER¹, P. BIEN¹, K. MUNOZ¹, R. ASTER²; ¹Trius Therapeutics, Inc., San Diego, CA, ²Med. Coll. of Wisconsin, Milwaukee, WI.

Poster Session

206(D). Antimicrobial Susceptibility Testing 2008

Monday, 12:15 p.m. – 1:15 p.m. Hall C

- D-2250a** Automated PCR to Detect Methicillin-Resistant (MR) or -Susceptible (MS) *Staphylococcus aureus* (SA) in Blood Cultures (BC) and Wound Swabs (WS)

D. M. MUSER, M. GOEBEL, M. MATLOOBI, C. STAGER, M. PARTA; VA Med. Ctr., Houston, TX.

LATE-BREAKER ABSTRACT PRESENTATIONS

Poster Session

209(H). Antiretroviral Therapy: Complications

Monday, 12:15 p.m. – 1:15 p.m. Hall C

H-2312a Continuous Antiretroviral Therapy (ART) Decreases Bone Mineral Density: Results from the SMART Study

B. GRUND¹, A. CARR², the Insight Smart Study Group; ¹Univ. of Minnesota, Minneapolis, MN, ²St. Vincent's Hosp. and Univ. of NSW, Sydney, Australia.

Poster Session

214(K). Assessing the Value of MRSA Screening

Monday, 12:15 p.m. – 1:15 p.m. Hall C

K-3379a One-Year Follow Up of a Screening Program for MRSA Colonisation Upon Hospital Admission with a Rapid Molecular Technique

E. NULENS¹, P. DESCHEEMAER¹, R. DEURENBERG², E. STOBBERINGH², B. GORDTS¹; ¹Gen. Hosp. Saint-Jan, Brugge, Belgium, ²Maastricht Univ. Med. Ctr., Maastricht, Netherlands.

K-3379b Skin and Environmental Contamination by Patients with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Occurs Before Admission PCR Results Become Available

S. CHANG¹, C. J. DONSKEY^{2,1}, U. STIEFEL^{2,1}, J. L. CADNUM², A. K. SETHI¹; ¹Case Western Reserve Univ., Cleveland, OH, ²VA Med. Ctr., Cleveland, OH.

Poster Session

224(V). Herpes Viruses

Monday, 12:15 p.m. – 1:15 p.m. Hall C

V-3562a Genital Shedding of Cytomegalovirus (CMV) is More Strongly Associated with HIV Shedding than Herpes Simplex Virus (HSV)

C. CASPER^{1,2}, J. HITTI², K. PAUL², M. HUANG², S. E. COHN³, A. LUQUE³, A. WALD², L. COREY^{1,2}, R. W. COOMBS², M. BOECKH^{1,2}; ¹Fred Hutchinson Cancer Res. Ctr., Seattle, WA, ²Univ. of Washington, Seattle, WA, ³Univ. of Rochester, Rochester, NY.

Slide Session

228(L). Emerging Issues in Gastrointestinal Infections

Monday, 1:30 p.m. – 4:00 p.m. Independence E (Grand Hyatt)

L-3595a Outbreak of *Salmonella* Serotype Saintpaul (SSP) Infections Associated with Multiple Raw Produce Items: United States, 2008

I. T. WILLIAMS, for the SSP Investigation Team; CDC, Atlanta, GA.

Slide Session

264(G2) Pediatric Vaccines

Tuesday, 8:30 a.m. – 11:00 a.m. Room 151B

3:30 p.m.

G2-3748 Effectiveness of Pentavalent Rotavirus Vaccine (RV5) in U.S. Clinical Practice

J. BOOM¹, J. TATE², L. SAHNI¹, M. RENCH¹, M. PATEL², C. BAKER¹, U. PARASHAR²; ¹Ctr. for Vaccine Awareness and Res., Texas Children's Hosp. (TCH), Houston, TX, ²CDC, Atlanta, GA.

Poster Session

280(C2). Acinetobacter: Global Impact

Tuesday, 11:15 a.m. – 12:15 p.m. Hall C

C2-3871a Resistance to Colistin in *Acinetobacter baumannii* Mediated by the PmrBA Two-Component System

M. D. ADAMS; Case Western Reserve Univ., Cleveland, OH.

Poster Session

289(F1). New Macrolides

Tuesday, 11:15 a.m. -12:15 p.m. Hall C

F1-3972a Single Oral Dose Pharmacokinetics and Safety of CEM-101 in Healthy Subjects

J. G. STILL¹, K. CLARK¹, T. P. DEGENHARDT¹, D. SCOTT¹, P. FERNANDES¹, M. J. GUTIERREZ²; ¹Cempra Pharmaceuticals Inc., Chapel Hill, NC, ²Comprehensive Phase One, Miramar, FL.

Poster Session

294(H). HIV Pharmacology

Tuesday, 12:15 p.m. – 1:15 p.m. Hall C

H-4059a Raltegravir (RAL) Pharmacokinetics (PK) and Safety in Adolescents: Preliminary Results from IMPAACT P1066

S. NACHMAN¹, E. P. ACOSTA², A. WIZNIA³, H. TEPPLER⁴, M. C. LONG², B. HOMONY⁴, B. GRAHAM⁵, C. WORRELL⁶, P. SAMSON⁷, E. HANDELSMAN⁸; ¹SUNY Stony Brook, Stony Brook, NY, ²Univ. of Alabama, Birmingham, AL, ³Jacobi Med. Ctr., Bronx, NY, ⁴Merck Res. Labs, North Wales, PA, ⁵Frontier Sci. and Technology Res. Fndn., Buffalo, NY, ⁶NICHHD, Bethesda, MD, ⁷Harvard Sch. of Pub. Hlth., Boston, MA, ⁸NIAID, Bethesda, MD.

Poster Session

300(K). Nosocomial Infections and the Environment

Tuesday, 12:15 p.m. – 1:15 p.m.

Hall C

K-4124a The Use of Vaporized Hydrogen Peroxide Room Decontamination During an Outbreak of *Acinetobacter baumannii* at a Long-Term Acute Care Hospital

A. RAY¹, F. PEREZ¹, M. JAKUBOWYCZ¹, P. DIMICK¹, M. R. JACOBS¹, K. ¹Univ. Hosp. Case Med. Ctr., Cleveland, OH, ²VAMC, Cleveland, OH.

K-4214b Adherence to Hydrogen Peroxide Vapor (HPV) Decontamination Reduces VRE Acquisition in High-Risk Units

C. L. PASSARETTI¹, J. A. OTTER², P. LIPSETT¹, A. SHANGRAW¹, J. MYERS¹, T. ROSS¹, K. CARROLL¹, T. M. PERL¹; ¹Johns Hopkins, Baltimore, MD, ²Bioquell, Horsham, PA.

Poster Session

301(K). Gastrointestinal Infections: Food for Thought

Tuesday, 12:15 p.m. – 1:15 p.m.

Hall C

L-4134a A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Prulifloxacin as Therapy for Traveler's Diarrhea

H. L. DUPONT^{1,2}, Z. D. JIANG¹, R. B. WALSH³; ¹St. Luke's Episcopal Hosp., Houston, TX, ²Univ. of Texas-Houston Sch. of Publ. Hlth. and Med. Sch., Houston, TX, ³Optimer Pharmaceuticals, Inc., San Diego, CA.

L-4134b Multistate Outbreak of Human *Salmonella* serotype Schwarzengrund Infections Caused by Contaminated Dry Dog Food: Northeastern United States, 2006-2008

C. BARTON BEHRAVESH¹, T. AYERS¹, M. HOEKSTRA¹, A. FERRARO², M. DEASY III², M. MOLL², E. VILLAMIL³, J. AUSTIN¹, I. WILLIAMS¹, S. Schwarzengrund Outbreak Investigation Team; ¹CDC, Atlanta, GA, ²Pennsylvania Dept. of Hlth., Harrisburg, PA, ³New York State Dept. of Hlth., Albany, NY.

Poster Session

302(V). Respiratory Viruses I: Influenza and RSV

Tuesday, 12:15 p.m. – 1:15 p.m.

Hall C

V-4154a A Double-Blind, Placebo-Controlled Study of Intravenous Peramivir in Acute Influenza Patients

S. KOHNO¹, H. KIDA², M. MIZUGUCHI³, J. SHIMADA⁴, S-021812 Clinical Study Group; ¹Nagasaki Univ., Nagasaki, Japan, ²Hokkaido Univ., Sapporo, Japan, ³Univ. of Tokyo, Tokyo, Japan, ⁴St. Marianna Univ. Sch. of Med., Kawasaki, Japan.

Poster Session

303(V). Respiratory Viruses II

Tuesday, 12:15 p.m. – 1:15 p.m.

Hall C

V-4164a High Prevalence of Bocavirus in Young Children Attending Daycare

E. T. MARTIN¹, J. KUYPERS², S. CHAMBERS³, M. FAIRCHOK³, J. A. ENGLUND^{1,2,4}; ¹Seattle Children's Hosp., Seattle, WA, ²Univ. of Washington, Seattle, WA, ³Madigan Army Med. Ctr., Ft. Lewis, WA, ⁴Fred Hutchinson Cancer Res. Ctr., Seattle, WA.

Slide Session

304(B). Immunology of Respiratory Infections

Tuesday, 1:30 p.m. – 4:00 p.m.

Room 206

4:15 p.m.

B-4174a Adalimumab (TNF mAb) Treatment of Life-Threatening TB Paradoxical Reaction Precipitated by Adalimumab Withdrawal

C. VAN VUUREN¹, S. POTGIETER¹, R. S. WALLIS^{2,3}; ¹Univ. of the Free State, Bloemfontein, South Africa, ²UMDNJ-NJMS, Newark, NJ, ³Pfizer, Inc., New London, CT.

